Exploiting Plasmodium Mitochondrial Pathways for Next‐Generation Antimalarial Drug Development: Prospects and Updates
Drug Development Research · 2026-11 · 87 (7)
DOI: 10.1002/ddr.70399 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Development Research, online erschienen am 23.10.2026. Verfasst von Rohit Nehra und 4 weiteren Autor:innen. Beteiligte Einrichtung: ICMR-National Institute of Malaria Research, Dwarka, India. Hauptthemen laut MEDLINE: Antimalarials, Plasmodium, Mitochondria, Drug Development. Die Arbeit nennt 97 Literaturangaben.
Abstract (Originalsprache)
Despite decades of control efforts, the global burden of malaria remain and emergence of drug‐resistant Plasmodium parasites is threatening the effectiveness of treatment and elimination strategies. The mitochondrion of Plasmodium species, the causative agents of malaria, has unique structural and biochemical properties that differ significantly from those of the mammalian host, making it a promising target. The primary mitochondrial targets for antimalarial drug development are cytochrome bc1 (complex III), dihydroorotate dehydrogenase (DHODH), NADH dehydrogenase, succinate dehydrogenase (complex II), cytochrome C oxidase (complex IV), Cardiolipin synthase (CLS), and ubiquinone biosynthesis pathways. The validation of mitochondrial targets through clinical trials and the new prospects for combination therapies to overcome resistance and attain long‐term antimalarial efficacy are highlighted in this review. We examine the structural and functional adaptations of the parasite's mitochondrial ETC (electron transport chain), highlighting the mechanism of action and resistance profiles of established inhibitors alongside novel chemical scaffolds (e.g., DSM265, ELQ‐300). Recent studies have focused on endochin‐like quinolones (ELQs) and related 4(1H)‐quinolones, which target the ubiquinone‐reduction (Qᵢ) site or exhibit dual Q o /Qᵢ inhibition. This review provides a comprehensive analysis of the current landscape of antimalarial drug discovery targeting the Plasmodium mitochondrion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ICMR-National Institute of Malaria Research, Dwarka, India.
- Department of Biochemistry, Kurukshetra University, Kurukshetra, India.
ORCID-Profile: Rohit Nehra, Kuldeep Singh, Himmat Singh, Praveen Kumar Bharti, Suman Dhanda
Zitieren
APA
Nehra, R., Singh, K., Singh, H., Bharti, P. K., & Dhanda, S. (2026). Exploiting Plasmodium Mitochondrial Pathways for Next‐Generation Antimalarial Drug Development: Prospects and Updates. Drug Development Research, 87(7). https://doi.org/10.1002/ddr.70399
Vancouver
Nehra R, Singh K, Singh H, Bharti PK, Dhanda S. Exploiting Plasmodium Mitochondrial Pathways for Next‐Generation Antimalarial Drug Development: Prospects and Updates. Drug Development Research. 2026;87(7). doi:10.1002/ddr.70399
BibTeX
@article{Nehra2026,
author = {Nehra, Rohit and Singh, Kuldeep and Singh, Himmat and Bharti, Praveen Kumar and Dhanda, Suman},
title = {Exploiting Plasmodium Mitochondrial Pathways for Next‐Generation Antimalarial Drug Development: Prospects and Updates},
journal = {Drug Development Research},
year = {2026},
volume = {87},
number = {7},
doi = {10.1002/ddr.70399}
}
EUVIMED